CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced the addition of two experts in drug discovery and development to its leadership team.
Alan Collis, Ph.D., who was formerly Executive Director of DMPK at Forma Therapeutics, joined the Nimbus team part-time in October 2018 and in his full-time role will serve as Vice President of Preclinical Development. Jennifer Rocnik, Ph.D., who has served as Nimbus’ Director of Oncology Biology since 2015, has been promoted to Vice President, Biology.
“These additions to Nimbus’ leadership team, as well as the recent appointment of Peter Tummino as our Chief Scientific Officer, reflect our ongoing commitment to our pipeline of medicines and to conducting truly transformative scientific inquiry,” said Jeb Keiper, M.S., MBA, President and Chief Executive Officer at Nimbus. “Alan and Jenn’s expertise in drug discovery and development will no doubt accelerate our momentum toward broadening our pipeline to include new highly sought-after targets in metabolic disease, cancer and immune-inflammatory disorders.”
Dr. Alan Collis is an expert in discovery chemistry, candidate selection and development with over three decades of experience. Prior to joining Nimbus, he was Executive Director of DMPK at Forma Therapeutics, in which role he transitioned two projects into Phase II, four through IND and five through preclinical profiling. Before that, Dr. Collis served as Novartis’ Executive Director of Scientific and Strategic Planning and Global Leader of the Metabolism and Pharmacokinetics group. In that role, he advised on all aspects of project strategy, compound progression and business planning. Earlier in his career, Dr. Collis held significant leadership roles in medicinal chemistry in the large pharma settings of Aventis, Rhone-Poulenc Rorer and Pfizer. He earned his Ph.D. and B.Sc. from the University of Manchester Institute of Science and Technology.
Dr. Jennifer Rocnik joined Nimbus as Director of Oncology Biology in 2015 and has led the company’s programs in oncology and immuno-oncology as well as efforts to identify new targets across the portfolio. Dr. Rocnik has more than a dozen years of drug discovery experience in both biotech and pharma where she has led programs from target identification to development candidate nomination. Prior to joining Nimbus, Dr. Rocnik held roles of increasing responsibility in the oncology division of Sanofi, where she led cross-functional global drug discovery project teams. Before Sanofi, Dr. Rocnik was at Novartis Institutes for Biomedical Research, where she led a number of target validation and early drug discovery programs. Dr. Rocnik received her Ph.D. in molecular medicine from Boston University School of Medicine and completed her postdoctoral fellowship at Brigham and Women’s Hospital.
About Nimbus Therapeutics
Nimbus Therapeutics is a
biotechnology company headquartered in Cambridge, Massachusetts (USA).
Nimbus is pioneering the application of highly-advanced computational
technologies to the design and development of novel treatments for
substantial and underserved human diseases. The company’s focus on
metabolic diseases, cancer and immune-inflammatory disorders reflects
the mechanistic relationship between these disorders, and Nimbus’
ability to rapidly tackle well validated targets as well as those that
have proven intractable to others. The company’s LLC/subsidiary
architecture enables diverse and synergistic partnerships to deliver
breakthrough medicines. To learn more, please visit www.nimbustx.com.
